Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of AMG0001 in subjects with critical limb ischemia
2016-003491-41Phase 3Completed
- Sponsor
- AnGes, Inc.
- Start
- Oct 2016
- Modality
- Gene Therapies, Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of beperminogene perplasmid in chronic limb-threatening ischemia (CLTI), sponsored by AnGes, Inc. Primary endpoint: Long-term safety of AMG0001. Started Oct 2016; status: completed.
02
Drugs
beperminogene perplasmid
03
Conditions
chronic limb-threatening ischemia (CLTI)
Beyond the preview
Go deeper on 2016-003491-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003491-41.